TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01291927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreas-sparing duodenectomy
Description: Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Description: The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
Study: NCT01314924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: 70% cocoa

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: 70% cocoa
Study: NCT02714049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sex therapy
Description: 60 minutes each time, in person or on the telephone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
Study: NCT02867605

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Hyaluronan
Study: NCT03551470

Intervention type: PROCEDURE
Intervention: Robotic one-stage colorectal and liver resection
Study: NCT01593618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UMFollowUp
Description: Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
Study: NCT02889159

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Candida albicans antigen
Description: 0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: histamine phosphate
Description: 0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: imiquimod 5% cream
Description: Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
Study: NCT01357382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
Study: NCT06103656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Chinese Herbal Medication
Description: Capsules, 26 month course, starting 2 months pre-OIT.
Study: NCT02889159

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tape Stripping
Description: At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
Study: NCT01271543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation
Description: General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
Study: NCT01994512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression without fusion
Description: Decompressive surgery of both central and lateral component of the stenosis.
Study: NCT04840381

Intervention type: BEHAVIORAL
Intervention: Questionnaire administrations
Description: Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
Study: NCT01994512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression with fusion
Description: Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
Study: NCT00286949

Intervention type: DRUG
Group type: OTHER
Intervention: Atomoxetine
Description: Open Label uncontrolled active Drug intervention
Study: NCT01601834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340 or Placebo
Description: PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340 or Placebo
Description: PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
Study: NCT00401336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging multiecho gradient-echo sequence
Description: Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
Study: NCT05440682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CP group
Description: Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
Study: NCT04054648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bedtime administration of the participant's pre-existing antihypertensive medications
Description: Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
Study: NCT01771133

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention group
Description: The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
Study: NCT04293159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG (Enterolactis duo®)
Description: Lactobacillus casei DG (Enterolactis duo®)
Study: NCT02439775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ multi-electrode renal denervation system
Description: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
Study: NCT06103656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo
Description: Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Omalizumab
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase
Study: NCT04470856

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test (EEOT)
Description: An occlusion manoeuvre during the end of expiration for 20 seconds
Study: NCT01275170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose
Study: NCT02007356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-γ positive selected T-cells
Study: NCT00431457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an intracranial electrode
Description: Implantation of an intracranial electrode will be followed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implantation of an intracranial electrode
Description: Implantation of an intracranial electrode will be followed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amygddohyppocampertomy
Description: Resective surgery
Study: NCT03773757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IN-PEACE Dementia Care Coordination
Description: Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
Study: NCT02572050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Gastrectomy with D2 LND
Description: Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
Study: NCT03063827

Intervention type: DRUG
Intervention: OnabotulinumtoxinA 200 UNT
Description: Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urothelial sensory protein levels
Description: Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urothelial sensory protein levels
Description: Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
Study: NCT03056690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0819
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT01585766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 30 MG-IV
Description: Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 60 MG-SC
Description: Participants received SC injection of 60 mg MEDI-551 on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO-IV-SC
Description: Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 100 MG-IV
Description: Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 300 MG-SC
Description: Participants received SC injection of 300 mg MEDI-551 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 600 MG-IV
Description: Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
Study: NCT03967470

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bacterial spray
Description: Bacterial spray containing bacteria that do not cause underarm malodor

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacterial spray
Description: Bacterial spray containing bacteria that do not cause underarm malodor
Study: NCT00203450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonegran
Description: zonisamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT02690961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo multiple doses
Study: NCT01275170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose
Study: NCT02690961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo multiple doses
Study: NCT01701258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose placebo capsule during the fMRI session only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose placebo capsule during the fMRI session only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose placebo capsule during the fMRI session only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose placebo capsule during the fMRI session only
Study: NCT05630937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-01940153E
Description: Route of administration: intravenous (IV) solution
Study: NCT00177424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study: NCT02310542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS albumin dialysis system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS albumin dialysis system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPAD albumin dialysis system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPAD albumin dialysis system
Study: NCT01852890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous chemotherapeutic

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT00911014

Intervention type: OTHER
Intervention: Questionnaire
Description: From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
Study: NCT02173756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine gel
Description: 1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
Study: NCT03669965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth
Study: NCT01852890

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT03837899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab / Tremelimumab Combination Therapy
Description: Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase.
Study: NCT03669965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth
Study: NCT01275170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7655
Description: 125 mg intravenous (IV) over 30 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem + Cilastatin
Description: 250 mg IV over 30 minutes as a single dose
Study: NCT03464344

Intervention type: OTHER
Group type: OTHER
Intervention: neurological, neuropsychological and MRI evaluation
Description: neurological, neuropsychological and MRI evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: neurological, neuropsychological and MRI evaluation
Description: neurological, neuropsychological and MRI evaluation
Study: NCT01172548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT02751151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: have Levulan Kerastick (aminolevulinic acid) solution
Description: Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered